This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Bioethics Remove COVID-19 Remove Pharmaceutical Industry Related Topics
COVID-19 Vaccine Public Health Governance FDA Licensing Health Insurance More Related Topics >
article thumbnail

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

SEPTEMBER 28, 2023

By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.

COVID-19 205
COVID-19 COVID-19 Vaccine Pharmaceutical Industry Governance 205
article thumbnail

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Health Populi

FEBRUARY 22, 2021

The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. consumers trusted the biotech health industry segment compared with the pharmaceutical segment.

COVID-19 154
COVID-19 COVID-19 Vaccine Pharmaceutical Industry Public Health 154
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 50,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024